Cite
HARVARD Citation
Hahn, A. et al. (2020). A Phase I Study of Alpha‐1, 3‐Galactosyltransferase‐Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. Oncologist. pp. 121-e213. [Online].